|Bid||0.0000 x 800|
|Ask||0.0000 x 800|
|Day's Range||4.0000 - 4.0100|
|52 Week Range||2.4300 - 6.8400|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Although the masses and most of the financial media blame hedge funds for their exorbitant fee structure and disappointing performance, these investors have proved to have great stock picking abilities over the years (that's why their assets under management continue to swell). We believe hedge fund sentiment should serve as a crucial tool of an […]
Moody's Investors Service ("Moody's") placed the ratings of Diplomat Pharmacy, Inc. ("Diplomat") under review for upgrade. Moody's changed the outlook to rating under review from developing. OptumRx is part of UnitedHealth Group Incorporated, which has senior unsecured debt rated A3 with a stable outlook.
M&A Monday in healthcare, with two of the deals involving cancer drugs. Merck is buying ArQule for $2.7 billion. It's the latest move by a U.S. drug maker to buy targeted cancer therapies. The deal strengthens Merck's oncology business well before its blockbuster cancer drug Keytruda loses its market exclusivity in 2028. ArQule's crown jewel that Merck wants is a precision drug that tailors treatment to a patient's genetic profile. California's biotech firm Synthorx is getting $2.5 billion in cash, selling itself to France's Sanofi. Synthorx focuses on therapies for people with cancer or auto-immune disorders. Sanofi is stepping up its drive to expand into cancer drugs under its new chief executive. Like Merck, Sanofi is also paying a rich premium. UnitedHealth, by contrast, is buying Diplomat Pharmacy at a 31% discount. Diplomat has been losing customers in its pharmacy benefits management business due to intense competition. Shares of acquirers Merck, Sanofi and UnitedHealth fell, while Arqule and Synthorx shares doubled in early trading. Diplomat shares plunged more than 30%.
Benzinga Pro's Stocks To Watch For Monday Merck (MRK) - Reported it will purchase ArQule (ARQL) in a deal valued at $2.7 billion. The purchase price for ArQule was $20/share in cash. ArQule shares were ...
Diplomat Pharmacy (NYSE: DPLO ) shares are trading lower on Monday after the company received a $4 per share acquisition offer from UnitedHealth Group's (NYSE: UNH ) OptumRx. Optum is UnitedHealth Group's ...
UnitedHealth Group Inc. said Monday it will spend about $300 million to acquire Diplomat Pharmacy Inc., a specialty pharmacist that had been struggling to compete in an industry increasingly dominated by health-industry giants.
Diplomat Pharmacy Inc on Monday agreed to UnitedHealth Group Inc's over $300 million buyout offer, weeks after it warned of its inability to pay off some of its debt amid intense competition in the pharmacy benefits management business. Health insurer UnitedHealth's offer of $4 per share in cash is at a 31% discount to Diplomat's closing price on Friday and is a far cry from the company's peak market valuation in 2015, when its shares had traded as high as $52. "It's hard for me to call it (UnitedHealth's offer) a godsend on a stock that has gone from over $50 to now a take-under... I would not call this a great day for Diplomat," Baird analyst Eric Coldwell told Reuters.
Diplomat, the Flint, Mich., pharmacy- and infusion-services provider, had considered a number of strategic options.
Diplomat Pharmacy, Inc. (NYSE:DPLO) investors will be delighted, with the company turning in some strong numbers with...
Diplomat Pharmacy Inc (NYSE: DPLO) cautioned investors on Tuesday that it has "substantial doubts" related to its ability to continue functioning as a business. Wells Fargo analyst Jamie Stockton maintained a Market Perform rating on Diplomat with a price target lowered from $5.50 to $3. If the company opts not to sell itself and remain public, it would be valued at eight times EV/EBITDA on EBITDA estimates of $85 million, the analyst said.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 12) ACADIA Pharmaceuticals Inc (NASDAQ: ACAD ) Allergan ...
Moody's Investors Service ("Moody's") downgraded the ratings of Diplomat Pharmacy, Inc. ("Diplomat") including the Corporate Family Rating to Caa1 from B3, the Probability of Default Rating to Caa1-PD from B3-PD, the senior secured rating to Caa1 from B3 and the Speculative Grade Liquidity Rating to SGL-4 from SGL-3. The downgrade of the Corporate Family Rating to Caa1 from B3 reflects the recent decision by a large payer to begin excluding Diplomat from its specialty pharmacy network later this month, raising concerns about Diplomat's competitive position.
Shares of Diplomat Pharmacy, Inc. (NYSE: DPLO), a Flint, Michigan-based independent provider of specialty pharmacy and infusion services, plummeted more than 50% Tuesday after the company warned investors it faces an existential threat. Revenue declined year-over-year from $1.373 billion to $1.301 million, and the pharmacy benefit manager segment revenue fell from $170 million to $82 million as the segment's total volume fell from 1,931,000 to 922,000. Diplomat's earnings report includes a warning that it may not be able to meet its total net leverage and interest coverage ratio covenants as part of its credit agreement for the period ending Dec. 31, 2019.
Diplomat Pharmaceuticals (DPLO) delivered earnings and revenue surprises of -40.00% and 11.81%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
The 700+ hedge funds and famous money managers tracked by Insider Monkey have already compiled and submitted their 13F filings for the second quarter, which unveil their equity positions as of June 28. We went through these filings, fixed typos and other more significant errors and identified the changes in hedge fund portfolios. Our extensive […]
It's nice to see the Diplomat Pharmacy, Inc. (NYSE:DPLO) share price up 11% in a week. But only the myopic could...
Moody's Investors Service ("Moody's") downgraded the ratings of Diplomat Pharmacy, Inc. ("Diplomat") including the Corporate Family Rating to B3 from B2, the Probability of Default Rating to B3-PD from B2-PD, and the senior secured rating to B3 from B2. At the same time, Moody's affirmed the SGL-3 Speculative Grade Liquidity Rating.
Diplomat Pharmacy, Inc. (NYSE: DPLO ) reported second-quarter earnings at $2.13 per share. The company reported revenue of $1,288 million, compared to $1,416 million last year. Despite the positive earnings ...